Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tamiflu Cleared For Pediatric Flu Prevention

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche's antiviral oseltamivir is now approved for treatment and prevention of influenza in children, adolescents and adults.

You may also be interested in...



Tamiflu Safety Will Get FDA Committee Review Nov. 27

The Pediatric Advisory Committee will evaluate reported neuropsychiatric and behavioral events from patients taking Roche’s influenza product.

Tamiflu Safety Will Get FDA Committee Review Nov. 27

The Pediatric Advisory Committee will evaluate reported neuropsychiatric and behavioral events from patients taking Roche’s influenza product.

Tamiflu For All Ages: Roche’s Influenza Antiviral Cleared In Europe For Adolescents

European Medicines Agency recommends monitoring of potential psychiatric adverse events associated with oseltamivir but does not feel a warning is warranted.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061434

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel